

aprepitant (Emend®)

(No. 132/04)

Merck Sharpe & Dohme

Summary of Advice

08 November 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

Advice: following a full submission.

Aprepitant is accepted for restricted use within NHS Scotland for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy.

The antiemetic regimen incorporating aprepitant was superior to one regimen (where dexamethasone alone was used in the delayed phase of treatment), for the prevention of cisplatin-induced nausea and vomiting in the acute and delayed phases. It should be initiated only by appropriate hospital based specialists.

Professor David H Lawson
Chairman